{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DSGN",
  "name": "Design Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/DSGN/",
  "json_url": "https://frontierpicks.com/dossiers/DSGN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "A new 52-week high of $15.94 printed in August with no company release since the 2026-08-03 Q2 update, which pushed the next hard data to Q1 2027. RSI(14) 73.9 at the $14.99 close (2026-08-21) and +21.9% for the month, into a 30-day calendar with no company-dated event; the Q4-2026 registrational-plans update is the next real checkpoint.",
  "invalidation_trigger": "A weekly close below $13.50 gives back the entire August advance and returns the name to the post-2026-05-18 range; secondarily, the Q4-2026 registrational-plans update arriving without a defined endpoint framework, cohort design or filing path for DT-216P2.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage and pre-revenue: all value sits in DT-216P2, DT-168 and DT-818 readouts, with no product revenue to cushion a data miss.",
    "Weighted-average shares outstanding were 62.5M in Q2 2026 — a thin count in which one dated headline moves the quote in double digits either way.",
    "RESTORE-FA's primary efficacy endpoint has been endogenous blood FXN protein percent change from baseline since 2026-08-03, no longer a clinical scale such as mFARS.",
    "Cash, equivalents and investment securities were $207.4M at 2026-06-30; runway was guided into 2029 at the Q1 2026 report, so a raise is optional rather than forced.",
    "Friedreich ataxia competitive set: approved Skyclarys/omaveloxolone (Biogen/Reata), Larimar (LRMR) nomlabofusp, PTC Therapeutics (PTCT) vatiquinone.",
    "Scheduled readouts cluster in 2027 — RESTORE-FA 12-week in Q1 2027, DT-168 and DT-818 during 2027 — leaving a long stretch with no company-dated data."
  ],
  "body_markdown": "## Current Thesis\nThe leg being bought is platform validation: GeneTAC small molecules restoring endogenous frataxin in Friedreich ataxia (DT-216P2), with the same chemistry aimed at Fuchs endothelial corneal dystrophy (DT-168) and myotonic dystrophy type 1 (DT-818). Nothing in that story changed between 2026-08-08 and 2026-08-21. The quote did. Shares closed $14.99 on 2026-08-21 against a 52-week high of $15.94 in the adjusted daily series — above the $15.79 high standing two weeks earlier — so a new high was registered in a stretch during which the company issued no press release at all. StockTitan's overview page, retrieved at that close, shows an August gain of 21.9%, 71.0% year-to-date, 191.1% over 52 weeks and a market capitalisation of $938.1M.\n\nThe fundamental frame is still the one set on 2026-08-03: RESTORE-FA modified to a 1 mpk go-forward dose in a 10-patient, 12-week cohort, with endogenous blood FXN protein percent change from baseline as the primary efficacy endpoint, 12-week topline guided to Q1 2027 and a registrational-plans update guided to Q4 2026. In the same release DT-168 Phase 2 biomarker data slipped from 2H-2026 into 2027 on manufacturing supply of the eye-dropper formulation. The August advance therefore happened into an empty calendar rather than into news.\n\n**The narrative is maturing.** The name is still working — 71.0% year-to-date through 2026-08-21 — and the theme has been running since the 2026-07-12 flip, but headline supply has stopped: the last company release is dated 2026-08-03 and the next scheduled clinical readout is Q1 2027. Well known inside the Friedreich ataxia pool, still bid, no fresh catalyst flow.\n\n## Bull Case\n- 2026-05-18 RESTORE-FA four-week IV data at 1 mpk: whole-blood FXN mRNA +65%, FXN-M/FXN-E protein +22–27%, muscle FXN mRNA +42%, mean mFARS +6.4 points, PROMIS Fatigue improvement above 5 points against a 3-point minimal-important-change bar.\n- The 2026-08-03 re-cut is executable within a year: 10 patients, 12 weeks, primary endpoint on the exact measure the four-week data already moved, with topline in Q1 2027 rather than a multi-year clinical-scale study.\n- Dedicated ownership disclosed on 2026-08-14: Sirenia Capital filed an initial Schedule 13G for 9.5% beneficial ownership and Point72 filed a 13G/A showing 3.8% (2.37M shares).\n- No open-market insider selling appears in the public filing list through 2026-08-21; the most recent Form 4 is a 2026-06-11 grant of 30,000 stock options at $10.55 to George Simeon.\n- Balance sheet does not force a financing into the readout: cash, equivalents and investment securities of $207.4M at 2026-06-30 against a Q2 net loss of $20.2M (R&D $16.4M, G&A $5.8M); runway was guided into 2029 at the Q1 2026 report.\n- Q2 EPS of $(0.32) beat the $(0.34) consensus (2026-08-03), and the sell-side rating set is uniform — 6 analysts, Strong Buy consensus per MarketBeat (2026-08-08).\n\n## Bear Case\n- The next hard datapoint is Q1 2027. DT-168 FECD biomarker data moved out of 2026 on 2026-08-03 for a manufacturing reason — eye-dropper formulation supply — which prices the second asset's optionality lower without saying anything about the chemistry.\n- The Q1-2027 primary efficacy endpoint is a biomarker. A clean blood FXN protein result does not establish that frataxin restoration translates into function, and the registrational status of that endpoint is exactly what the Q4-2026 update has to define.\n- Ten patients, twelve weeks, in a slowly progressive degenerative disease. On 2026-05-18 the market marked the four-week open-label dataset down 25.5% to a $10.22 close, which is the standing evidence for how small open-label cohorts get received here.\n- Cash and investments stepped down from $222.8M at 2026-03-31 to $207.4M at 2026-06-30. With the quote 6.0% under its 52-week high and no filed takedown as of 2026-08-21, a raise into strength remains available and unannounced.\n- Published targets no longer sit above the quote in aggregate: Investing.com's 6-analyst average is $14.67 (low $12, high $18), WallStreetZen shows $15.25, MarketBeat's consensus is $16.50 (all retrieved 2026-08-22) against the $14.99 close.\n- Transient ALT elevations in three patients, all on background omaveloxolone (2026-05-18), carry into a longer-duration cohort at the same dose.\n\n## Setup & Price Structure\n- 2026-08-21 close $14.99, 6.0% under the $15.94 52-week high; the shares are up 36.6% over three months and 21.9% in August alone (StockTitan, 2026-08-21).\n- RSI(14) reads 73.9 at $14.99 versus 77.3 at the $13.99 close on 2026-08-07. Measured: the oscillator eased while price added roughly a dollar. Inferred: momentum is thinning at the highs — on its own that is a weak signal, not a reversal.\n- The August leg cleared the prior swing close of $15.19 (2026-07-10) and the old $15.79 high; the $13.50 area is the shelf that carried the June–July reclaim after the May drawdown.\n- Crowding observables, stated without a verdict: two beneficial-ownership filings on the same day (2026-08-14); a Strong Buy rating from all 6 covering analysts (2026-08-08); the last close above the 6-analyst average target; RSI above 70 at both the 2026-08-07 and 2026-08-21 closes; no earnings date inside 30 days to force a repricing.\n- Aggregators also report an Oppenheimer Outperform with a $21 target raised from $18, but they disagree on whether that action dates to May or August 2026, so it is not counted here as a fresh datapoint.\n- Weighted-average shares outstanding of 62.5M in Q2 2026 keep the float thin enough that a single dated release moves the quote in double digits, as 2026-05-18 (-25.5%) and 2026-04-28 (+23.3%) both showed.\n\n## Catalyst Calendar (next 30 days)\n- **No company-dated event is confirmed between 2026-08-22 and 2026-09-21.** The last release is 2026-08-03; the 10-Q and 8-K were filed the same day.\n- **~2026-09-08 (est.)** — early-September healthcare investor conference season. No DSGN participation had been announced as of 2026-08-22. The company presented at Oppenheimer's healthcare conference (2026-02-25), Leerink (2026-03-10) and Jefferies (May 2026), so a September appearance is plausible but unscheduled; it is the only realistic venue inside the window for protocol detail.\n- **~2026-11-05 (est.)** — Q3 2026 results and business update. First scheduled checkpoint on whether the Q1-2027 timeline holds and on burn against the $207.4M at 2026-06-30.\n- **Q4 2026 (company-guided)** — registrational-plans update for DT-216P2.\n- **Q1 2027 (company-guided)** — RESTORE-FA 12-week topline from the 10-patient 1 mpk cohort.\n\n## What Would Change Our Mind\nThe structure that matters is the June–July reclaim shelf near $13.50, which the entire August advance sits on top of. A weekly close below $13.50 would give back that advance and put the name back in the post-2026-05-18 range, with the next dated data still two quarters away — that is the gradeable break.\n\nTwo non-price conditions would do the same work. First, the Q4-2026 registrational-plans update arriving without a defined endpoint framework, cohort design or filing path for DT-216P2, which would leave the Q1-2027 readout unable to resolve anything regulatory. Second, any slip of the Q1-2027 12-week topline disclosed at the ~2026-11-05 Q3 report, following the DT-168 move out of 2026 — a second timeline reset would make execution, not biology, the operative question.\n\nOn the other side, the read strengthens if the company announces a September conference slot with protocol detail, or if the Q4-2026 update names a specific regulatory path for a blood FXN protein endpoint.\n\n## Correlation Notes\n- Friedreich ataxia complex: Larimar Therapeutics (LRMR, nomlabofusp), PTC Therapeutics (PTCT, vatiquinone) and the approved Skyclarys/omaveloxolone franchise (Biogen/Reata). A peer readout or regulatory decision can reprice DSGN on a day with no DSGN release, in either direction — the four-week data itself was read against omaveloxolone background therapy.\n- Myotonic dystrophy type 1 read-across for DT-818: Avidity Biosciences (RNA) and Dyne Therapeutics (DYNE) set the sentiment frame for DM1 assets ahead of DSGN's own 2027 Phase 1 MAD data.\n- Small-cap clinical biotech beta (XBI) and rate expectations dominate the tape on days with no company news, which — given the last release is dated 2026-08-03 — is currently most days.\n- With 62.5M weighted-average shares and two beneficial-ownership filings dated 2026-08-14, a concentrated register amplifies both directions; 13F disclosures for the September quarter are not due until mid-November.",
  "first_seen": "2026-04-30",
  "last_analyzed": "2026-08-22T08:13:48+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}